Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

1.870 -0.050 (-2.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Top movers in Monday's session
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Discover the most active stocks in Monday's session.
Stay updated with the latest market activity on Monday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
Earnings Outlook For Invivyd
 
Via Benzinga
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
Invivyd Touts Encouraging Data From COVID-19 Antibody Trial, Stock Jumps
Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million. 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
From Invivyd
Via GlobeNewswire
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
From Invivyd
Via GlobeNewswire
Which stocks are moving after the closing bell on Friday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Monday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised
From Invivyd
Via GlobeNewswire
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
Invivyd's new data highlights Pemgarda's activity against SARS-CoV-2 XEC and over 75% of variants, with consistent neutralization since Omicron BA.1. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
From Invivyd
Via GlobeNewswire
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
From Invivyd
Via GlobeNewswire
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
From Invivyd
Via GlobeNewswire
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Invivyd
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
 
Via Benzinga
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
From Invivyd
Via GlobeNewswire
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
From Invivyd
Via GlobeNewswire
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
From Invivyd
Via GlobeNewswire
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.